Key Findings from the NADINA Trial at ASCO 2024

EP: 1.ASCO 2024: Addressing Unmet Needs in Melanoma Treatment and Management

Now Viewing

EP: 2.Key Findings from the NADINA Trial at ASCO 2024

EP: 3.ASCO 2024: Impact of RELATIVITY-047 on Metastatic Melanoma Management

EP: 4.ASCO 2024 Highlights: Long-Term Data and the Future of Combination Therapies in Melanoma

EP: 5.Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma

EP: 6.ASCO 2024: Emerging Data on Brenetafusp (IMC-F106C) ImmTAC Bispecific in Melanoma

EP: 7.Melanoma Research Beyond ASCO 2024: Upcoming Advances and Insights

Video content above is prompted by the following:

• Discuss the data presented at the 2024 ASCO Annual Meeting on the phase 3 NADINA trial (NCT04949113) of neoadjuvant nivolumab plus ipilimumab vs adjuvant nivolumab in patients with macroscopic, resectable stage III melanoma.
  • What was the objective of this study?
  • How was this study designed/what methodology was used?
  • What results were presented?
• Please provide your key takeaways from this study. How might these findings impact the treatment of patients with melanoma?
• What are the key considerations when deciding between neoadjuvant and adjuvant therapy for patients with resectable melanoma?